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ABSTRACT:
Purpose: Brachytherapy is a highly valued and effective palliative treatment for lung cancer,
especially as it reduces intensity of dyspnoea and other symptoms arising from tumours inside
the respiratory tract. In some cases, due to the location of the lesion brachytherapy is a treatment
of choice. However, its curative role is unclear. A combination treatment of brachytherapy
and an external beam irradiaton may play a significant role when the mediastinal Iymph nodes
are involved.
The paper presents the results of treatment ot advanced lung cancer patients by external beam
irradiation and brachytherapy, and the role ot this palliative treatment is discussed.
Material and methods: Between May 1999 and March 2000 at the Greatpoland Cancer Centre tifteen
patients with advanced lung cancer were treated by HDR brachytherapy and palliative external beam
irradiation using the method ot hypofractionation. The patients' age ranged between 39 to 80 years,
mean: 54.3 years. The treatment consisted ot external beam irradiation (total dose ot 20-30 Gy),
and a weekly high dose rate (HDR) brachytherapy (three tractions ot 7.5 or 10 Gy, at 1 cm tram
the source). In three cases the treatment was started with external irradiation, whereas in 12 cases
the first stage was brachytherapy. During the patients' c1inical and endobronchial tollow-up
ot 1, 3 and 6 months, local remission and regression ot difficulties in breathing, cough, pain
and haemoptysis were assessed.
Results: In all our patients subjective improvement (regression of all symptoms) was found on the tirst
check-up tollowing treatment. In one case complete remission of the tumour lasted tor over 6 months,
in 9 cases partial remission and in two cases progression were found. Severe complications due
to the high total local dose were not observed.
Conclusions: Combined palliative treatment (intraluminal brachytherapy and external beam
irradiation) in advanced lung cancer was an efficient method that led to regression ot symptoms
and impravement ot well-being in many patients.
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INTRODUCTION
In the palliative treatment for lung cancer
brachytherapy is one of the effective
methods of controlling dyspnoea caused
by obturation. Due to the location of the
lesion inside the bronchial tubes, the degree
ot c1inical advancement, and patients'
general condition, in some patients brachy-
therapy is a treatment of choice, which,
when carried out on an out-patient basis,
takes a short time and leads to a smali
number ot early complications [1,2,3,4,
5,6,7,8].
Indications for palliative brachytherapy
include: local relapse following earlier
teletherapy, patients with non-small-cell
lung cancer accompanied by intense
symptoms, mostly dyspnoea caused by
obturation ot the bronchial tree. The con-
traindications include: lesion located in the
peripheral part of the lung, Pancoast's
tumour, superior vein caval syndrome,
and massive haemoptysis.
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A combination treatment ot teletherapy
and brachytherapy may be applied using
radical doses, and aims at curing the patient
(brachytherapy administered to increase
the dose within the tumour). It mayaiso
be administered tor palliative purposes:
teletherapy employed to reduce the lymph
nodes compressing the bronchi trom
the outside, or to restore the patency
ot the bronchi. A combined radiotherapy
makes it possible to increase the dose
at the vicinity ot the tumour over a relatively
short period ot time. Moreover, the main
cause ot inettective teletherapy is due
to the lack ot local cure, which provides
an additional reason why both the above
mentioned modalities should be used
in combination. [9,10,11,12].
Radical combined therapy has been
a subject ot many clinical studies since
in a number ot papers no signiticant
increase in the patients' survival rate
as compared with teletherapy used alone
has been reported. However, the available
data indicate that the incidence ot local
recoveries is high [2,8,9]. What is also
important is that radical therapy may
be applied in only a smali number
ot patients as the progress ot the disease
in most patients is usually highly advanced.
The aim ot the present work is a preli-
minary assessment ot the etticiency
ot a combined palliative therapy tor ad-
vanced non-small-cell lung cancer.
MATERIAL AND METHOOS
Palliative combined teletherapy and bra-
chytherapy was applied in patients who
were not qualitied tor radical radiotherapy
on the grounds ot the advanced stage
ot the disease, as well as in those with
impaired patency ot the respiratory tract and
the presence ot Iymph nodes in the media-
stinum. The therapy was conditioned on
the degree ot etticiency higher than
50 (according to the Karnotsky score)
and the presence ot the tumour veritied
by histologically accesible endobroncho-
scopy.
Between May 1999 and March 2000
15 patients with lung cancer were treated
at the Greatpoland Cancer Centre using
HDR brachytherapy in combination with
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palliative teletherapy employing the method
ot hypotractionation. The patient's age
ranged between 39 and 80 years, mean:
54.3 years. In the group ot patients under
study were 12 men and 3 women, squa-
mous-cell carcinoma being detected
histologically in 11 cases and adenocarci-
noma in tour cases.
(A) Brachytherapy
Following pre-medieation one or two
endobronchial eatheters were placed
in the bronchi, veritied radiologieally.
In the treatment 10 Ci ot Iridium-192 was
applied using an HDR-GAMMAMED
12i unit. To calculate the dose distribution
an ABACUS computer programme was
employed. Three traetions ot 7.5 Gy were
administered in 9 patients, and three
tractions ot 10 Gy were given to 6 patients,
at 1 cm trom the applieator's axis. A higher
traetionated dose was used in patients with
the tumour obturating the bronchi by more
than 50%. The irradiation (the area within
the treatment dose) covered the site
ot the visible tumour and the tragment
ot the bronchi 2 cm distally and proximally
trom the tumour. The treatment was applied
at one-week intervals.
(B) Teletherapy
The mediastinum was irradiated trom two
opposite tields by photons ot 9 MV
ar gamma rays (Co-60) using the method
ot hypotractionated dośes: 5 x 4 Gy/ week
ar 10 x 3 Gy/week to the total dose
ot 20 (30) Gy. Due to the availability
ot the neeessary therapeutic equipment,
in three patients the treatment was started
with teletherapy, whereas in 12 patients
it was initiated with HDR brachytherapy.
The interval between teletherapy and bra-
chytherapy was on the average 4 weeks.
In one case, three months later, a single
additional dose ot 10 Gy was given caused
by the sudden recurrence 01 intense
dyspnoea.
The patients were tollowed-up clinically,
radiologically and bronchoscopically
tor 1, 2, 3 and 6 months by assessing loeal
remission, regression ot dyspnoea, cough
and haemoptisis.
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RESULTS
The patients tolerated the combination
therapy successfully and showed no com-
plications. After the termination of the tre-
atment subjective improvement (regression
of dyspnoea, cough, pain and haemoptisis)
was found in all patients, including three
patients who registered complete remission
(GR) and 12 patients who showed partial
remission (PR) verified on endobro-
choscopic and radiological examination
(Table 1). Regression of dyspnoea, cough,
haemoptisis, pain and atelectasis was
confirmed in 15/15, 10/15, 6/8, 7/10
and 5/7 patients, respectively. Atelectasis
partly regressed in two cases. The loca-
Iization of the tumour did not have any
significant effect on the efficiency of the tre-
atmenł.
The sequence of the treatment (brachy-
therapy or teletherapy) did not have any
significant effect on the results (Table 2).
During the 6-month follow-up no effect
of the dose (within specified Iimits) and that
ot the treatment sequence on the regre-
ssion outcome of complaints was detected.
In one case complete remission lasted more
than 6 months, and in two cases cones-
cutive examinations revealed progression
ot the disease (Table 2). During the 6-month
tollow-up three patients died, two in the se-
cond month and one in the third month).
One ot them died of a cardiovascular dise-
ase, and in the case ot two others no intor-
mation was available.
labie 1. Clinical and bronscoscopic assessment according to selected clinical features.
Clinical features After 4 weeks After2 After3 After6N= months months months
eR PR
11 Patient's age:
less than 54,3 years 9 2 7 7 6 6
more than 54,3 years 6 1 5 6 4 4
21 Symptoms:
- dyspnoea, 15 15 13 10 9
- cough, 15 10 5 11 8 7
- haemoptisis, 8 6 2 6 6 6
-
pain, 10 7 3 8 7 7
- atelectasis 7 5 2 6 5 5
31 Bronchoscopic examination:
al tumour localization:
- trachea, 2 1 1 2 1 1
-
trachea + primary bronchus, 4 O 4 3 1 1
- left primary bronchus, 2 1 1 1 1 1
- right primary bronchus, 5 1 4 5 5 5
- lobar bronchus 2 O 2 2 2 2
bl diameter ot the stenosis:
< 1/3 2 1 1 2 2 2
1/3 - 2/3 6 2 4 6 5 5
> 2/3 4 O 4 3 3 3
complete 3 O 1 2 o O
Total: 3/15 12/15 13/15 10/15 10/15
20,0% 80,0% 86,7% 66,7% 66,7%
N - number ot patients
GR - complete remission
PR - partial remission
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Table 2. Clinical and bronchoscopic assessment according to the method ot treatment.
N= After4 Follow - UpMethod 01 treatment
weeks
PR 2 3 6eR months months months
11 tele (20Gy) + 3 x 7,5 Gy 1 o 1 o o o
21 tele (20Gy) + 3 x 10 Gy 2 o 2 2 2 2
31 3 x 7,5 Gy + tele (20 Gy) 7 2 5 6 5 5
41 3 x 7,5 Gy + tele (30 Gy) + 10 Gy 1 o 1 1 1 1
51 3 x 10 Gy + tele (20,30 Gy) 4 1 3 4 2 2
N - number ot patients
eR -complete remission
PR -partial remission
tele - teletherapy with higher tractional doses
DlseUSSION
There is a large number ot reports
on the efficiency ot palliative teletherapy
tor the advanced lung cancer (grade lilA-B)
applied separately. In this group ot patients
the mean survival time does not exceed
7 to 10 months. These detinitely poor re-
sults ot treatment have provided the ratio-
nale tor seeking new methods ot dose
tractionation and ways ot combining radia-
tion therapy with chemotherapy, and re-
cently with brachytherapy [9,13,14].
There have been reports ot cases ot long
survival times in patients with locally
advanced lung cancer treated radically with
a combined therapy ot brachytherapy
and teletherapy [10,12,15], however
the number 01 such cases is very smalI.
The combination therapy is thought to in-
crease the distant survival rate, although
there is a lack ot randomized studies
to corroborate this hypothesis. Most reports
have been concerned with radical combi-
nation treatment ot the oesophageal lung
(stage I and II) [5,7,12,16].
More knowledge has been gained on pa-
lIiative treatment. The technique ot palliative
irradiation aims at neutralising the sym-
ptoms such as dyspnoea, cough, hae-
moptisis, and thus at improving the patient's
well-being. In most patients brachytherapy
applied separately makes it possible
to reduce the intensity ot the above sym-
ptoms [17,18,19,20,21]. There is, however,
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a group ot patients with advanced
oesophageal cancer who may benefit trom
the combined therapy ot brachytherapy and
palliative teletherapy. In these patients,
dyspnoea is caused not only by the intra-
bronchial tumour, but also by the presence
ot Iymph nodes exerting external pressure
(compression) on the bronchi. Teletherapy
aims at reducing those Iymph nodes
exerting external pressure on the bronchus,
whereas teletherapy helps to restore pa-
tency ot the bronchus. By combining
the above two methods ot palliative
radiation therapy the dose delivered
to the tumour's vicinity can be increased
over a relatively short time and the local
control improved [10,11,12,14].
The traction ot positive responses to tre-
atment, according to many authors, ranges
between 80% and 90% ot the patients
treated, in most cases ending with complete
remission [22,23]. The situation seems
to be unclear concerning the dose recom-
mended in brachytherapy. The doses ex-
ceeding 10 Gy at 1 cm distance trom
the catheter's axis lead to the increase
in the number ot positive responses,
however the number ot cases with com-
plications, mostly haemoptisis, also incre-
ases [25,22,24]. This is the reason why,
in the treatment ot our patients, we used
single doses ot 7.5 Gy or 10 Gy, Iike most
ot other authors [1,4,5,6,7].
One report provides an analysis
ot 406 patients who had undergone bra-
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chytherapy [24], 324 ot which were treated
with brachytherapy alone, 65 patients rece-
ived brachytherapy tollowing teletherapy,
and 17 were subjected to an alternate
combined treatmenł. Single doses
ot 15 Gy , 20 Gy and 10 Gy were admi-
nistered in 79.6%, 1B.5% and 1.9% ot all
cases, respectively. The most common
complication was aggravation ot cough
in the 2nd and 3rd week after the termination
ot the treatmenł. The multitactorial statistical
analysis showed that the most important
risk tactors of acute complications were:
increase in the dose to 20 Gy, earlier
coagulation with lasers, and second
application ot brachytherapy. In 65%
of cases, controi examination revealed
complete remission.
[B] made a comparative analysis ot re-
trospective results in a group ot patients
treated palliatively by brachytherapy alone
(3 x 7.5 Gy) and a group of patients additio-
nally treated by teletherapy up to the dose
ot 37.5 Gy in 15 fractions. The first group
registered decrease in dyspnoea (4B%),
cough (57%) and haemoptisis (97%).
However, no difference was found
in the outcome ot the treatment between
the above two groups.
[14] have presented the results of a pro-
spective randomized study of 95 patients
with advanced lung cancer. The patients
were divided in two groups: the tirst group
was treated by teletherapy alone, and the
other underwent combined treatment
(teletherapy and brachytherapy). In brachy-
therapy the dose employed was 7.5 Gy
in two fractions, whereas teletherapy used
a dose of 30 Gy ar 60 Gy. Significantly
better effects of treatment (regression
of dyspnoea lasting more than three
months) were obtained in the group treated
by the combination method. However,
the patients in this group had thetumour
localized in the primary bronchus.
Our results ot treatment are similar
to those described by other authors
[B,9,1 0,12]. Periodically recurrent regre-
ssion of dyspnoea was found in all patients.
In some cases the improvement occurred
within a few hours after the termination
of brachytherapy. Regression of dyspnoea
was associated with less intense cough,
smalier haemoptosis, lower pain in the me-
diastinum ar fewer symptoms of atelectasis.
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Six months later subjective and bronco-
scopic improvement continued in two-thirds
of all patients.
The short follow-up in aur patients does
not make it possible to assess the survival
time, however regression ot clinical
symptoms and improvement in the patients'
well-being constitute the best evidence
of the efficiency of the treatment in our
group of patients.
The complication most commonly
occurring within the period ot 6 months after
the termination of the treatment, as descry-
bed in the literature, is that ot haemoptosis
ot various intensity and the post-radiation
inflammation. Most common late compli-
cation is that ot bronchial stenosis [26].
Complications are found more frequently
after earlier laser coagulation of the tumour
inside the bronchus. We have not observed
any acute after-treatment complications
in our group ot patients.
CONClUSIONS
1. Combined treatment (HDR brachy-
therapy and hypofractionated teletherapy)
of advanced lung cancer may be reco-
mmended in cases ot intrabronchial tumour
associated with mediastinal Iymph nodes
exerting pressure on the bronchi.
2. In 66.7% ot cases treated by the combi-
nation therapy regression ot dyspnoea
and improvement in well-being lasting more
than 6 months were obtained.
3. A high local total dose did not affect
the frequency of complications.
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